Lung Transplant HCV, Pilot Study

EARLY_PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

September 19, 2017

Primary Completion Date

January 2, 2020

Study Completion Date

May 31, 2026

Conditions
Lung Transplant InfectionHepatitis C
Interventions
DRUG

Sofosbuvir-velpatasvir (400 mg/100 mg)

Patients will have standard monitoring with HCV RNA and liver panel assessment at 2 week intervals until HCV is undetectable and then at the end of treatment and 3 and 6 months following its completion. Post-operative transplant care and immunosuppression will be carried on as usual transplant practice at Toronto General Hospital.

DEVICE

Ex Vivo Lung Perfusion (EVLP)

Normothermic EVLP is a method of donor lung preservation, assessment, treatment, and repair of injured organs. This method allows donor lungs to be treated for at least 12h under protective physiological conditions.

Trial Locations (1)

M5G 2N2

University Health Network Toronto General Hospital, Toronto

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Gilead Sciences

INDUSTRY

lead

University Health Network, Toronto

OTHER